Hospital Universitario Ramón y Cajal
Hospital Universitario Ramón y Cajal
Madrid, Spain42 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Pegtibatinase as a Treatment for Participants With Classical Homocystinuria (HCU) Receiving Standard of Care Treatment | Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Nutritional and Metabolic Diseases, Skin and Connective Tissue Diseases, brain disorder, central nervous system disorder, connective tissue disorder, hereditary disease, homocystinuria, hyperhomocysteinemia, inborn disorder of amino acid metabolism, inborn errors of metabolism, metabolic disease, nervous system disorder | Recruiting | Phase 3 | 2026-10-08 | NCT06247085 | |
| Pulmonary Embolism Registry From Short-Term Emergency to Long-Term Follow-Up and Surveillance | Disease Attributes, Embolism, Embolism and Thrombosis, Emergencies, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Thromboembolism, Ventricular Dysfunction, Ventricular Dysfunction, Right, cardiac arrest, cardiovascular disorder, chronic thromboembolic pulmonary hypertension, heart disorder, lung disorder, pulmonary embolism, respiratory system disorder, vascular disorder, venous thromboembolism | Recruiting | Not stated | 2026-10-07 | NCT07855679 | |
| A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia (ExCIT) | Patients With Chemotherapy-Induced Thrombocytopenia | Recruiting | Phase 3 | 2026-10-01 | NCT07286032 | |
| Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake | brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, ischemic stroke, nervous system disorder, stroke disorder, vascular disorder | Recruiting | Phase 4 | 2026-09-30 | NCT06571149 | |
| Sacituzumab govitEcan in THYroid Cancers | Neoplasms by Histologic Type, carcinoma, differentiated thyroid carcinoma, epithelial neoplasm, neoplasm, thyroid gland undifferentiated (anaplastic) carcinoma | Recruiting | Phase 2 | 2026-09-16 | NCT06235216 | |
| A Non-interventional Study of Participants With BPDCN Treated With Chemotherapy | CD4+/CD56+ hematodermic neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, hematologic disorder, hematopoietic and lymphoid system neoplasm, leukemia, lymphoma, malignant histiocytosis, neoplasm, skin disorder, skin neoplasm | Recruiting | Not stated | 2026-09-15 | NCT07785180 | |
| Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Not applicable | 2026-09-14 | NCT04905069 | |
| External Multicenter Validation of the APTTO Model for Prolonged APTT Using Clot Waveform Analysis | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, blood coagulation disease, blood platelet disease, cardiovascular disorder, coagulation protein disease, hematologic disorder, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder, vascular disorder, vascular hemostatic disease, von Willebrand disease (hereditary or acquired) | Recruiting | Not stated | 2026-09-11 | NCT07418099 | |
| CRS Questionnaire Validation Project | Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps | Recruiting | Not stated | 2026-09-09 | NCT06970977 | |
| Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. | Advanced Breast Cancer; ER-positive Breast Cancer; ESR1 Gene Mutation; HER2-negative Breast Cancer | Recruiting | Phase 3 | 2026-08-24 | NCT06382948 | |
| A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endometrium adenocarcinoma, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Recruiting | Phase 2 | 2026-08-21 | NCT05548296 | |
| Severe Complications During Ventricular Tachycardia or Premature Ventricular Complex Ablation | Arrhythmias, Cardiac, Cardiac Complexes, Premature, Cardiac Conduction System Disease, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Tachycardia, Ventricular Premature Complexes, cardiovascular disorder, heart disorder, ventricular tachycardia | Recruiting | Not stated | 2026-08-20 | NCT07777744 | |
| A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET | digestive system neuroendocrine neoplasm | Active, not recruiting | Phase 3 | 2026-07-28 | NCT05050942 | |
| Fecal Microbiome Transplantation in Cirrhosis: Trial in Patients With Decompensated Cirrhosis | Decompensated Cirrhosis | Recruiting | Phase 3 | 2026-07-20 | NCT06533852 | |
| A Study of JNT-517 in Participants With Phenylketonuria (PKU) | Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Nutritional and Metabolic Diseases, brain disorder, central nervous system disorder, hereditary disease, inborn disorder of amino acid metabolism, inborn errors of metabolism, metabolic disease, nervous system disorder, phenylketonuria | Recruiting | Phase 3 | 2026-07-08 | NCT06971731 | |
| Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma | Neoplasms by Histologic Type, adenocarcinoma, carcinoma, cholangiocarcinoma, epithelial neoplasm, neoplasm | Active, not recruiting | Phase 3 | 2026-07-06 | NCT05948475 | |
| NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide | Newly Diagnosed Multiple Myeloma | Recruiting | Phase 3 | 2026-06-25 | NCT05558319 | |
| A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis | Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver disease | Active, not recruiting | Phase 3 | 2026-06-01 | NCT03900429 | |
| A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE) | Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Nutritional and Metabolic Diseases, Skin and Connective Tissue Diseases, brain disorder, central nervous system disorder, connective tissue disorder, hereditary disease, homocystinuria, hyperhomocysteinemia, inborn disorder of amino acid metabolism, inborn errors of metabolism, metabolic disease, nervous system disorder | Enrolling by invitation | Phase 3 | 2026-05-28 | NCT06431893 | |
| Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, renal cell carcinoma, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma, urinary system disorder | Recruiting | Phase 2 | 2026-05-08 | NCT05363280 | |
| A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis | Hemic and Lymphatic Diseases, Hypertrophy, Myeloproliferative Disorders, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Splenomegaly, anemia, blood platelet disease, bone marrow disorder, hematologic disorder, hemorrhagic disease, primary myelofibrosis | Active, not recruiting | Phase 3 | 2026-04-30 | NCT03165734 | |
| PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-04-29 | NCT06172127 | |
| Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder | Recruiting | Phase 2 | 2026-04-22 | NCT06180356 | |
| Safety and Performance of a Silicone Implant for Fecal Incontinence Treatment (SimplyFI) | Digestive System Diseases, Fecal Incontinence, digestive system disorder, intestinal disorder, rectal disorder | Active, not recruiting | Not applicable | 2026-03-20 | NCT05708612 | |
| Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 3 | 2026-03-18 | NCT06726265 |